an open-label study to evaluate safety and efficacy of 750 mg intravenous mepolizumab in subjects with steroid refractory eosinophilic cystitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-002353-20-BE

Enrollment

Registered

2008-05-28

Start date

2008-07-24

Completion date

Unknown

Last updated

2021-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eosinophilic cystitis

Interventions

Product Name: mepolizumab Product Code: BS-240563 Pharmaceutical Form:

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: steroid-dependent eosinophilic cystitis Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: life threatening or other serious illness serum creatinine > 3 ULN AST or ALT > 5 ULN platelets count < 50000/µL left ventricular ejection fraction < 20% positive pregnancy test

Design outcomes

Primary

Measure	Time frame
Main Objective: to be able to lower the steroid treatment used to alleviate symptoms;Secondary Objective: ;Primary end point(s): lowering or stopping of concomittant steroid treatment	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026